The rationale for this distinction is the emergence of reliable AD biomarkers that can measure beta-amyloid deposition, pathologic tau, and neurodegeneration (collectively termed the ATN framework), which are detectable up to 30 years before symptomatic cognitive impairment (4). The gene discussed is MAPT; the disease is Alzheimer disease.